Product Image

Contributor Information

  • Name Daniel Croft ; Justin Bower ; Heather Mckinnon
  • Institute Cancer Research UK, Glasgow: The Beatson Institute

Tool Details

  • Tool name: MDA-MB-231 TetOn-3G MRCK? cell line
  • Alternate names: Serine/threonine-protein kinase MRCK beta, CDC42-binding protein kinase beta, CDC42BP-beta, DMPK-like beta, Myotonic dystrophy kinase-related CDC42-binding kinase beta, MRCK beta, Myotonic dystrophy protein kinase-like beta
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MDA-MB-231 D3H2LN-Luc cell line
  • Organism: Human
  • Tissue: Breast
  • Cancer type: Triple negative breast (TNBC)
  • Disease: Cancer
  • Growth properties: Adherent cell line. Membrane blebbing/cytoskeleton reorganisation and migration induced in the presence of doxycycline.
  • Model: Transgenic
  • Conditional: Yes
  • Conditional description: MDA-MB-231 D3H2LN-Luc cell line that expresses tetracycline (Tet)-regulated transactivator Tet-On 3G regulated expression of MRCKβ. Therefore MRCKβ expression is induced in the presence of doxycycline.
  • Description: This cell line has been engineered to enable tetracycline inducible expression of the kinase MRCK?. MRCK? is a myotonic dystrophy kinase-related CDC42-binding kinase involved in regulating actin-myosin contractility and implicated in cancer metastasis. MRCK?, in conjunction with MRCKa, ROCK1 and ROCK2 kinases, initiates signalling events that lead to contractile force generation which powers cancer cell motility and invasion. The cell line is a derivative of a human breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when implanted orthotopically in mice (i.e. when implanted in the breast pad of mice). The cell line expresses luciferase enabling detection of the location of the cells using bioluminescent imaging. Useful for the study of breast cancer cell cytoskeleton reorganisation and cell migration. This cell line is derived from a triple negative breast cancer (TNBC) meaning it does not express oestrogen, progesterone or HER2 receptors. Treatment with doxycycline induced MRCKβ kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be 'leaky' in any clones tested.
  • Research area: Cancer; Cell Structure and Motility; Drug Discovery & Development; Genetic Studies Tools
  • Additional notes: Treatment with doxycycline induced MRCK? kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be 'leaky' in any clones tested. Tet-On System owned by TET Systems GmbH & Co. KG.

  • For Research Use Only

Target Details

  • Target: MRCKβ

Application Details

Handling

  • Format: Frozen
  • Growth medium: 10% FBS/MEM-EBSS/NEAA/NaPyr/Glutamine
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

    Download Icon
    Download Icon
    Download Icon
    Download Icon
  • Available on request

Related Tools

Product Image

ZR-75-1 [X-7] cell line

#154566
Product Image

ZR-75-1 [IX-6] cell line

#154551
Product Image

MCF10A-AKTm-1 cell line

#161210

References

  • •  Unbekandt et al. 2014. Cell Commun Signal. 12:54. PMID: 25288205.
  • •  A novel small-molecule MRCK inhibitor blocks cancer cell invasion.